Skip to Content
Merck
  • Proteomic profiling of human cancer pseudopodia for the identification of anti-metastatic drug candidates.

Proteomic profiling of human cancer pseudopodia for the identification of anti-metastatic drug candidates.

Scientific reports (2018-04-13)
Sunkyu Choi, Aditya M Bhagwat, Rasha Al Mismar, Neha Goswami, Hisham Ben Hamidane, Lu Sun, Johannes Graumann
ABSTRACT

Cancer metastasis causes approximately 90% of all cancer-related death and independent of the advancement of cancer therapy, a majority of late stage patients suffers from metastatic cancer. Metastasis implies cancer cell migration and invasion throughout the body. Migration requires the formation of pseudopodia in the direction of movement, but a detailed understanding of this process and accordingly strategies of prevention remain elusive. Here, we use quantitative proteomic profiling of human cancer pseudopodia to examine this mechanisms essential to metastasis formation, and identify potential candidates for pharmacological interference with the process. We demonstrate that Prohibitins (PHBs) are significantly enriched in the pseudopodia fraction derived from cancer cells, and knockdown of PHBs, as well as their chemical inhibition through Rocaglamide (Roc-A), efficiently reduces cancer cell migration.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-Prohibitin Antibody, from rabbit, purified by affinity chromatography
Sigma-Aldrich
Anti-Prohibitin-2/PHB2 Antibody, clone 7F8E3, clone 7F8E3, from rat
Roche
Cell Proliferation ELISA, BrdU (colorimetric), sufficient for ≤1,000 tests